Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Items 401–500 of 1,000
Fragment screening for drug leads by weak affinity chromatography (WAC-MS)
Ohlson, S., & Duong‐Thi, M. (2018) · Methods · doi:10.1016/j.ymeth.2018.01.011 · Cited by 33
Chang, F., Levengood, S. K. L., Cho, N., Chen, L., Wang, E., Yu, J. S., & Zhang, M. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800058 · Cited by 36
Microscale synthesis of multiblock copolymers using ultrafast RAFT polymerisation
Tanaka, J., Gurnani, P., Cook, A. B., Häkkinen, S., Zhang, J., Yang, J., Kerr, A., Haddleton, D. M., Perrier, S., & Wilson, P. (2019) · Polymer Chemistry · doi:10.1039/c8py01437j · Cited by 32
A Liquid Chromatography/Mass Spectrometry Method for Screening Disulfide Tethering Fragments
Hallenbeck, K. K., Davies, J. L., Merron, C., Ogden, P., Sijbesma, E., Ottmann, C., Renslo, A. R., Wilson, C., & Arkin, M. R. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217732072 · Cited by 35
Gawriljuk, V. O., Foil, D. H., Puhl, A. C., Zorn, K. M., Lane, T. R., Riabova, O., Makarov, V., Godoy, A. S., Oliva, G., & Ekins, S. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00460 · Cited by 32
Moshawih, S., Goh, H. P., Kifli, N., Idris, A. C., Yassin, H., Kotra, V., Goh, K. W., Liew, K. B., & Ming, L. C. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14062 · Cited by 39
“…started the HTS for this compound with 500,000 compounds in 1997; it was approved in 2007 by the U.S. Food and Drug Administration after several lead optimization stages from weak agonist till the final Maraviroc compound through structure-activity relationship strategies (Macarron et al., 2011).”
BackgroundHuang, K., Morato, N. M., Feng, Y., & Cooks, R. G. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300956 · Cited by 32
Saffari, A., Brechmann, B., Böger, C., Saber, W. A., Jumo, H., Whye, D., Wood, D., Wahlster, L., Alecu, J. E., Ziegler, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44264-1 · Cited by 32
Integration of Lead Discovery Tactics and the Evolution of the Lead Discovery Toolbox
Leveridge, M. V., Chung, C., Gross, J. W., Phelps, C. B., & Green, D. V. S. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218778503 · Cited by 33
Self-citationDantas, R. F., Evangelista, T. C. S., Neves, B. J., Senger, M. R., Andrade, C. H., Ferreira, S. B., & Silva, F. P. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1654453 · Cited by 34
Discovery of neuroprotective compounds by machine learning approaches
Fang, J., Pang, X., Yan, R., Lian, W., Li, C., Wang, Q., Liu, A.-L., & Du, G.-H. (2016) · RSC Advances · doi:10.1039/c5ra23035g · Cited by 31
Refining Early Antitumoral Drug Development
Ocaña, A., García‐Alonso, S., Amir, E., & Pandiella, A. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.09.003 · Cited by 31
NP Navigator: A New Look at the Natural Product Chemical Space
Zabolotna, Y., Ertl, P., Horvath, D., Bonachéra, F., Marcou, G., & Varnek, A. A. (2021) · Molecular Informatics · doi:10.1002/minf.202100068 · Cited by 31
Ng, G., Jung, K., Li, J., Wu, C., Zhang, L., & Boyer, C. A. (2021) · Polymer Chemistry · doi:10.1039/d1py01258d · Cited by 33
Wang, X., Zhu, H., Chen, D., Yu, Y., Liu, Q., & Liu, Q. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad351 · Cited by 34
“Although highthroughput screening (HTS) technology can screen drug combinations in vitro, the technology is expensive to build (Macarron et al. 2011) and cannot test the full combinational space.”
Drug discovery by targeting the protein–protein interactions involved in autophagy
Xiang, H., Zhou, M., Li, Y., Zhou, L., & Wang, R. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.016 · Cited by 31
“However, HTS is confronted with certain challenges, e.g ., low hit rate, weak potency, and false positives 129 .”
BackgroundNayarisseri, A. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/156802662019200701164759 · Cited by 34
Patient-derived stem cells: pathways to drug discovery for brain diseases
Mackay‐Sim, A. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00029 · Cited by 34
“Identification of a candidate gene is followed by genetically modified cell and Frontiers in Cellular Neuroscience www.frontiersin.org March 2013 | Volume 7 | Article 29 | 1 “fncel-07-00029” — 2013/3/25 — 20:40 — page 2 — #2 mouse models to identify the functions of the identified gene at cell and…”
BackgroundInfluentialExpanding Synthesizable Space of Disubstituted 1,2,4-Oxadiazoles
Tolmachev, A. A., Bogolubsky, A. V., Pipko, S. E., Grishchenko, A. V., Ushakov, D. V., Zhemera, A. V., Viniichuk, O., Konovets, A. I., Zaporozhets, O. A., Mykhailiuk, P. K., et al. (2016) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00103 · Cited by 30
Murali, V. S., Chang, B.-J., Fiolka, R. P., Danuser, G. M., Çobanoğlu, M. C., & Welf, E. S. (2019) · BMC Cancer · doi:10.1186/s12885-019-5694-1 · Cited by 34
Paciaroni, N. G., Perry, D. L., Norwood, V. M., Murillo-Solano, C., Collins, J. E., Tenneti, S., Chakrabarti, D., & Huigens, R. W. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00380 · Cited by 30
Ding, Y., Tang, H., Zhang, C., Li, W., Li, G., Zhang, Y., Xu, C. G., Zhao, F., Guo, Q., Guo, C. F., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100489 · Cited by 30
Ekins, S., Freundlich, J. S., & Reynolds, R. C. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400480s · Cited by 30
“However, Mtb screening hit rates tend to be in the low single digits, if not below 1% as seen elsewhere in drug discovery 13 .”
BackgroundMining collections of compounds with Screening Assistant 2
Guilloux, V. L., Arrault, A., Colliandre, L., Bourg, S., Vayer, P., & Morin‐Allory, L. (2012) · Journal of Cheminformatics · doi:10.1186/1758-2946-4-20 · Cited by 30
“Exploring biology through the activity of small molecules is an established paradigm used in drug research for several decades now [1,2].”
BackgroundThe European Lead Factory: A Blueprint for Public–Private Partnerships in Early Drug Discovery
Karawajczyk, A., Orrling, K. M., de Vlieger, J. S. B., Rijnders, T., & Tzalis, D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2016.00075 · Cited by 34
“Drug Discov Today (2015) 20(11):1310–6.”
BackgroundInfluentialDeMott, C. M., Girardin, R. C., Cobbert, J., Reverdatto, S., Burz, D. S., McDonough, K. A., & Shekhtman, A. G. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00879 · Cited by 30
Nys, G., & Fillet, M. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.07.011 · Cited by 33
Screening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
“In the past few years, a variety of screening technologies have been developed for drug discovery [46,47].”
BackgroundArman, S., Tilley, R. D., & Gooding, J. J. (2023) · The Analyst · doi:10.1039/d3an01423a · Cited by 30
The value of protein allostery in rational anticancer drug design: an update
Nussinov, R., & Jang, H. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2384467 · Cited by 31
“Another approach is high-throughput screening (HTS) [162] in the presence of orthos-teric ligands.”
The evolution and application of RNA-focused small molecule libraries
Taghavi, A., Springer, N. A., Zanon, P. R. A., Li, Y., Li, C., Childs‐Disney, J. L., & Disney, M. D. (2025) · RSC Chemical Biology · doi:10.1039/d4cb00272e · Cited by 32
McGivern, J. V., & Ebert, A. D. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.012 · Cited by 30
Miniaturized platform for high-throughput screening of stem cells
Tronser, T., Popova, A. A., & Levkin, P. A. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.005 · Cited by 29
“Performing large screens using microtiter plates (96–1536 well plates) is time consuming and laborious [11].”
BackgroundHarner, M. J., Mueller, L., Robbins, K. J., & Reily, M. D. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.06.005 · Cited by 30
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Fuchs, N. S., Zhang, L., Calvo‐Barreiro, L., Kuncewicz, K., & Gabr, M. T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010068 · Cited by 29
Translational semantics and infrastructure: another search for the emperor's new clothes?
Mullane, K., & Williams, M. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.004 · Cited by 30
Towards a hit for every target
Rees, S., Gribbon, P. M., Birmingham, K. E., Janzen, W. P., & Pairaudeau, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.19 · Cited by 29
Self-citationYoshimori, A., Kawasaki, E., Kanai, C., & Tasaka, T. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00625 · Cited by 35
Belov, A. M., Kozole, J., Bean, M. F., Machutta, C. A., Zhang, G., Gao, E. N., Ghislain, L., Datwani, S. S., Leveridge, M. V., & Annan, R. S. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02508 · Cited by 29
Computational compound screening of biomolecules and soft materials by molecular simulations
Bereau, T. (2020) · Modelling and Simulation in Materials Science and Engineering · doi:10.1088/1361-651x/abd042 · Cited by 32
“While high-throughput screening can probe impressive numbers of candidates, the requirements to synthesize, process, and/or characterize large libraries of compounds typically restricts the approach to particular systems and properties [8, 9, 10, 11, 12, 13].”
Georgiev, T., Migliorini, F., Ciamarone, A., Mueller, M., Biancofiore, I., Faviana, P., Bartoli, F., Kim, Y. S. P., Principi, L., Gilardoni, E., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01432-6 · Cited by 30
“Small organic binders are conventionally discovered by screening compound collections against targets of pharmaceutical interest, but insufficiently large library size often reduces the probability of discovering high-potency ligands 14,15 .”
Wen, X., Duan, Z., Liu, J., Lu, W., & Lu, X. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01565 · Cited by 28
Aguero, S., Mégy, S., Eremina, V. V., Калашников, А. И., Крылова, С. Г., Кулагина, Д. А., Александровна, Л. К., Fournier, M., Поветьева, Т. Н., Vorozhtsov, A., et al. (2021) · ACS Omega · doi:10.1021/acsomega.1c01786 · Cited by 28
Anti-Cancer Drug Screening with Microfluidic Technology
Monjezi, M., Rismanian, M., Jamaati, H., & Kashaninejad, N. (2021) · Applied Sciences · doi:10.3390/app11209418 · Cited by 30
“In this context, microfluidics could overcome the expensive and time-consuming process of combinatorial drug screening with high-throughput screening (HTS) of more compound candidates [18].”
BackgroundHTSDSF Explorer, A Novel Tool to Analyze High-throughput DSF Screenings
Martín-Malpartida, P., Hausvik, E., Underhaug, J., Torner, C., Martínez, A., & Macías, M. J. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167372 · Cited by 28
Recent advances in DNA-encoded dynamic libraries
Shi, B., Zhou, Y., & Li, X. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00007e · Cited by 29
Song, N., Dong, R., Pu, Y., Wang, E., Xu, J., & Guo, F. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00767-z · Cited by 28
“High-throughput screening in the laboratory is a common approach to finding drug candidates for important targets but it is time-consuming and costing [1].”
BackgroundWang, D., Feng, Y., Murtaza, M., Wood, S. A., Mellick, G. D., Hooper, J. N. A., & Quinn, R. J. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00987 · Cited by 28
Zimmermann, S., Gretzinger, S., Schwab, M.-L., Scheeder, C., Zimmermann, P. K., Oelmeier, S. A., Gottwald, E., Bogsnes, A., Hansson, M. D., Staby, A., et al. (2016) · Journal of Chromatography A · doi:10.1016/j.chroma.2016.08.025 · Cited by 28
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening
Matano, L. M., Morris, H. G., Wood, B. M., Meredith, T. C., & Walker, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.08.003 · Cited by 37
Ranganathan, A., Heine, P., Rudling, A., Plückthun, A., Kummer, L., & Carlsson, J. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00646 · Cited by 29
Recent Advances on the Selection Methods of DNA‐Encoded Libraries
Huang, Y., & Li, X. (2021) · ChemBioChem · doi:10.1002/cbic.202100144 · Cited by 28
Barcoded screening identifies nanocarriers for protein delivery to kidney
Wang, L., Zhou, W., Chen, H., Jia, X., Zheng, P., Jiang, H., Wu, M., Zhang, Y., Ding, Y., Peng, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56257-3 · Cited by 32
“It has been widely applied in drug discovery 8 , formulation optimization 9 – 11 , and target identi fi cation 12 – 14 .”
Niedringhaus, M. S., Dumitru, R., Mabb, A. M., Wang, Y., Philpot, B. D., Allbritton, N. L., & Taylor, A. M. (2015) · Scientific Reports · doi:10.1038/srep08353 · Cited by 27
Hansel, C. S., Plant, D., Holdgate, G. A., Collier, M. J., & Plant, H. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.010 · Cited by 28
Li, H., Zhao, X., Li, S., Wan, F., Zhao, D. Y., & Zeng, J. (2022) · iScience · doi:10.1016/j.isci.2022.105231 · Cited by 27
High‐Throughput Cellular Heterogeneity Analysis in Cell Migration at the Single‐Cell Level
Zhou, M., Ma, Y., Chiang, C., Rock, E. C., Luker, K. E., Luker, G. D., & Chen, Y. (2022) · Small · doi:10.1002/smll.202206754 · Cited by 28
THE DECADE OF THE RABiT (2005–15)
Garty, G. Y., Turner, H. C., Salerno, A., Bertucci, A., Zhang, J., Chen, Y., Dutta, A., Sharma, P. M., Bian, D., Taveras, M., et al. (2016) · Radiation Protection Dosimetry · doi:10.1093/rpd/ncw172 · Cited by 27
“The quality of HTS data is very high and often better controlled than data generated by lower-throughput biological tests((33)).”
BackgroundCancer drug discovery: recent innovative approaches to tumor modeling
Lovitt, C. J., Shelper, T., & Avery, V. M. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1214562 · Cited by 31
“In the 1990s, advances in robotics and miniaturized assay formats enabled high-throughput screening (HTS), an integral part of drug discovery practices [2].”
BackgroundThe emerging role of biosensor-based epitope binning and mapping in antibody-based drug discovery
Ditto, N. T., & Brooks, B. D. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1229295 · Cited by 28
Sanders, J. M., Beshore, D. C., Culberson, J. C., Fells, J. I., Imbriglio, J. E., Günaydin, H., Haidle, A. M., Labroli, M. A., Mattioni, B. E., Sciammetta, N., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01577 · Cited by 29
Ultrasensitive dynamic light scattering based nanobiosensor for rapid anticancer drug screening
Zheng, X. T., Goh, W. L., Yeow, P., Lane, D. P., Ghadessy, F. J., & Tan, Y. N. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.09.088 · Cited by 27
Biophysical screening in fragment-based drug design: a brief overview
Robson‐Tull, J. (2018) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzy015 · Cited by 29
Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins
Rectenwald, J. M., Guduru, S. K. R., Dang, Z., Collins, L. B., Liao, Y.-E., Norris-Drouin, J. L., Cholensky, S. H., Kaufmann, K. W., Hammond, S. M., Kireev, D., et al. (2020) · Molecules · doi:10.3390/molecules25040979 · Cited by 27
“Although this approach for HTS is usually automated, it is expensive to produce, maintain, and screen a library [15,16].”
Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies
Sokolov, A. V., Dostdar, S. A., Attwood, M. M., Krasilnikova, A. A., Ilina, A. A., Nabieva, A. S., Lisitsyna, A. A., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000317 · Cited by 28
Júnior, C. A. D. S., de Jesus, D. P., & Júnior, G. (2022) · Química Nova · doi:10.21577/0100-4042.20170893 · Cited by 27
Sarnpitak, P., Mujumdar, P., Taylor, P., Cross, M., Coster, M. J., Gorse, A., Krasavin, M., & Hofmann, A. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.006 · Cited by 27
IspE Inhibitors Identified by a Combination of In Silico and In Vitro High-Throughput Screening
Tidten, N., Grimaldi, R., Torrie, L. S., Frearson, J. A., Hunter, W. N., & Brenk, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035792 · Cited by 27
“[25,26,27].”
A comprehensive review of artificial intelligence for pharmacology research
Li, B., Tan, K., Lao, A. R., Wang, H., Zheng, H., & Zhang, L. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1450529 · Cited by 31
DRABAL: novel method to mine large high-throughput screening assays using Bayesian active learning
Soufan, O., Ba-Alawi, W., Afeef, M., Essack, M., Kalnis, P., & Bajić, V. B. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0177-8 · Cited by 27
“Mining high-throughput screening (HTS) assays, for example, can provide highly valuable findings for novel uses of existing drugs or proposing new drugs with specific biological effects [3].”
Backgroundcat-ELCCA: catalyzing drug discovery through click chemistry
Garner, A. L. (2018) · Chemical Communications · doi:10.1039/c8cc02332h · Cited by 28
An overview of techniques for multifold enhancement in solubility of poorly soluble drugs
Ansari, M. J. (2019) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2019-0035 · Cited by 26
Multiwell Raman plate reader for high-throughput biochemical screening
Kawagoe, H., Ando, J., Asanuma, M., Dodo, K., Miyano, T., Ueda, H., Sodeoka, M., & Fujita, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-95139-8 · Cited by 26
Seizures initiate in zones of relative hyperexcitation in a zebrafish epilepsy model
Niemeyer, J. E., Gadamsetty, P., Chun, C., Sylvester, S., Lucas, J., Ma, H., Schwartz, T. H., & Aksay, E. R. F. (2022) · Brain · doi:10.1093/brain/awac073 · Cited by 27
Measuring Protein Aggregation and Stability Using High-Throughput Biophysical Approaches
Kwan, T. O. C., Kolek, S., Danson, A. E., Reis, R. I., Camacho, I. S., Stewart, P. D. S., & Moraes, I. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.890862 · Cited by 26
“Introduced by pharmaceutical companies in the early 1990s for the massive screening of potential “drug-like” compounds, HTP approaches are extensively used by scientists today in academic laboratories, research institutes and industry in a variety of applications (Macarron et al., 2011; Kwan et al., 2019; Kiriiri, et…”
BackgroundKralj, S., Jukič, M., & Bren, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105727 · Cited by 26
“Various molecular filters are often used to increase the hit rates of drug development campaigns [11].”
BackgroundRoskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106847 · Cited by 26
Lead discovery and in silico 3D structure modeling of tumorigenic FAM72A (p17)
Pramanik, S., Kutzner, A., & Heese, K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2620-7 · Cited by 26
“Present finding based on structure-based drug design suggests that the lead molecule RSM can be used for the future setup of high-throughput screening (HTS) experiments with RSM as seed molecule and also to understand the possible biochemical antiFAM72A interaction-activity between RSM and FAM72A in a biological syste…”
BackgroundWeimar, M. R., Cheung, J., Dey, D., McSweeney, C. S., Morrison, M., Kobayashi, Y., Whitman, W. B., Carbone, V., Schofield, L. R., Ronimus, R. S., et al. (2017) · Applied and Environmental Microbiology · doi:10.1128/aem.00396-17 · Cited by 26
“The increase in throughput capacity of the phenotypic screening methods (24, 25), which was our primary goal, outweighs the small loss in potential targets missed under hydrogenotrophic conditions.”
BackgroundKinase inhibitor screening using artificial neural networks and engineered cardiac biowires
Conant, G., Ahadian, S., Zhao, Y., & Radisic, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12048-5 · Cited by 25
Liss, M., Radke, M. H., Eckhard, J., Neuenschwander, M., Dauksaite, V., von Kries, J. P., & Gotthardt, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198492 · Cited by 25
Druggable targets from coronaviruses for designing new antiviral drugs
Silva, L. R., Santos-Júnior, P. F. D. S., Brandão, J. D. A., Anderson, L., Bassi, Ê. J., de Araújo‐Júnior, J. X., Cardoso, S. H., & da Silva‐Júnior, E. F. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115745 · Cited by 26
Born, J., Huynh, T., Stroobants, A., Cornell, W. D., & Manica, M. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00889 · Cited by 28
Vittoria, A., Urciuoli, G., Costanzo, S., Tammaro, D., Cannavacciuolo, F. D., Pasquino, R., Cipullo, R., Auriemma, F., Grizzuti, N., Maffettone, P. L., et al. (2022) · Macromolecules · doi:10.1021/acs.macromol.2c00813 · Cited by 26
Label-free high-throughput screening via acoustic ejection mass spectrometry put into practice
Winter, M., Simon, R. P., Häbe, T. T., Ries, R., Wang, Y., Kvaskoff, D., Fernández‐Montalván, A. E., Luippold, A. H., Büttner, F. H., & Reindl, W. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.04.001 · Cited by 25
“High-throughput screening (HTS) is an established approach for the identification of chemical starting points for lead generation in drug discovery [1] .”
BackgroundTorng, W., Biancofiore, I., Oehler, S., Xu, J. H., Xu, J. A., Watson, I., Masina, B., Prati, L., Favalli, N., Bassi, G., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c01775 · Cited by 27
Mogire, R. M., Akala, H. M., Macharia, R. W., Juma, D. W., Cheruiyot, A. C., Andagalu, B., Brown, M. L., El‐Shemy, H. A., & Nyanjom, S. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186364 · Cited by 29
Paciaroni, N. G., Norwood, V. M., Ratnayake, R., Luesch, H., & Huigens, R. W. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115546 · Cited by 29
Ho, K., Roy, A., Foote, S., Vo, P. H., Lall, N., & Lin, C.-H. (2020) · Molecules · doi:10.3390/molecules25194516 · Cited by 25
“High-throughput screening (HTS) is a critical tool to expand biomedical knowledge of small molecules that can be used for the drug discovery industry [13].”
BackgroundNazari, M., Ekelöf, M., Khodjaniyazova, S., Elsen, N. L., Williams, J. D., & Muddiman, D. C. (2017) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7971 · Cited by 24
“Over the past two decades many strides have been made in miniaturization and automation of HTS, along with advancements in developing new assays and integrating rapid sampling with sensitive detection.[1,2]”
BackgroundZhou, Y., Shen, W., Peng, J., Deng, Y., & Li, X. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116328 · Cited by 24
Monobodies as tool biologics for accelerating target validation and druggable site discovery
Akkapeddi, P., Teng, K. W., & Koide, S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00188d · Cited by 24
Enzyme assays with supramolecular chemosensors – the label-free approach
Nilam, M., & Hennig, A. (2022) · RSC Advances · doi:10.1039/d1ra08617k · Cited by 24
GraphsformerCPI: Graph Transformer for Compound–Protein Interaction Prediction
Ma, J., Zhao, Z., Li, T., Liu, Y., Ma, J., & Zhang, R. (2024) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-024-00609-y · Cited by 24
“Standard high-throughput screening (HTS) [7] experimental methods enable rapid automated testing of thousands to millions of molecular samples.”
Xue, M., Liu, B., Cao, S., & Huang, X. (2025) · npj Drug Discovery. · doi:10.1038/s44386-025-00005-6 · Cited by 25
Camp, D., Campitelli, M. R., Carroll, A. R., Davis, R. A., & Quinn, R. J. (2013) · Chemistry & Biodiversity · doi:10.1002/cbdv.201200302 · Cited by 24
Chemical and Biological Properties of Frequent Screening Hits
Che, J., King, F. J., Zhou, B., & Zhou, Y. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300005y · Cited by 24
Assessing multiparametric drug response in tissue engineered tumor microenvironment models
Harris, A. R., Yuan, J. X., & Munson, J. M. (2017) · Methods · doi:10.1016/j.ymeth.2017.12.010 · Cited by 26
Maximizing gain in high-throughput screening using conformal prediction
Svensson, F., Afzal, A. M., Norinder, U., & Bender, A. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0260-4 · Cited by 25
“High throughput screening (HTS) has long been a paradigm in early-stage drug discovery [1].”
BackgroundSmall-Molecule Screening for Genetic Diseases
Markossian, S., Ang, K. K. H., Wilson, C. G. M., & Arkin, M. R. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021452 · Cited by 26
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.